Igor Bilinsky, Ph.D., serves as the Chief Operating Officer at Iovance Biotherapeutics Inc., a biotechnology company focused on developing novel cancer immunotherapies. Dr. Bilinsky brings a wealth of experience in the biopharmaceutical industry, with a strong background in operations, manufacturing, and process development. Prior to joining Iovance, he held leadership positions at several prominent companies, including Amgen and Genentech, where he played a key role in scaling up manufacturing processes and ensuring the successful launch of multiple products. At Iovance Biotherapeutics, Dr. Bilinsky is responsible for overseeing the company's day-to-day operations, with a particular focus on advancing the development and manufacturing of Iovance's innovative T cell therapies. His strategic vision and operational expertise have been instrumental in streamlining processes, optimizing resource allocation, and driving the company's growth. Under his leadership, Iovance has made significant progress in expanding its manufacturing capabilities and advancing its clinical pipeline, bringing the company closer to its goal of delivering life-changing treatments to patients with cancer. Dr. Bilinsky's contributions to the field of biopharmaceuticals extend beyond his role at Iovance. He is a respected thought leader and has been invited to speak at numerous industry conferences, sharing his insights on the challenges and opportunities in developing and manufacturing advanced therapies. His dedication to advancing the science of immunotherapy and his commitment to improving patient outcomes have earned him recognition within the industry and among his peers.